(INNS)
CABIRALIZUMAB(SLE)
KABIRALIZUMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA,ANTI-[HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR,CSF-1R,MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN (1-449) [HUMANIZED VH (HOMO SAPIENS IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), HINGE S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-218') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - HOMO SAPIENS IGKC*01, KM3 (112'-218')]; DIMER (228- 228":231-231")-BISDISULFIDE, RECOMMENDED INN: LIST 76(WHO)
CABIRALIZUMABUM(INN)